CHMP recommends EU approval of belzutifan plus lenvatinib for advanced ccRCC
Intl regulatory · Urology Times · 2026-11-13. Number 2 in the UrologyWatch Top 5 for November 15, 2026.
The European Medicines Agency's CHMP has issued a positive opinion recommending approval of belzutifan combined with lenvatinib for advanced clear cell renal cell carcinoma.
Why it matters: If ratified by the European Commission, this would add a new combination option for advanced ccRCC in Europe.
Source: Urology Times
Loading today's edition…